激素受体阳性T1-3N1M0乳腺癌21基因复发评分预后分析
该研究纳入287例激素受体阳性T1-3N1M0期乳腺癌患者,完成21基因检测并随访。中位随访74个月,RS≥26组远处转移率和复发率显著高于RS<26组,5年无病生存率显著更低。RS与肿瘤大小、分级、ER、PR及Ki-67相关,是影响远处转移和DFS的重要因素。
要点
- RS≥26组远处转移率23.4%,显著高于RS<26组的6.3%。
- RS≥26组5年DFS为85.1%,显著低于RS<26组的92.1%(P=0.006)。
- 年龄和肿瘤最大径是DFS的独立影响因素。
核心结论
- 21基因RS与激素受体阳性T1-3N1M0乳腺癌的肿瘤大小、分级、ER、PR及Ki-67相关。
- RS是影响该类患者远处转移和无病生存的重要因素。
研究设计与样本
- 回顾性收集287例T1-3N1M0期乳腺癌患者的临床病理资料,完成21基因检测并随访。
- 按RS<26和RS≥26分组,分析RS与临床病理特征、治疗及复发转移的关系,采用单因素和多因素Cox回归分析DFS影响因素。
主要发现
- 287例患者中位RS为16分,RS<26组240例,RS≥26组47例。
- 中位随访74个月,RS<26组复发转移率8.3%(20/240),其中局部复发2.1%(5/240),远处转移6.3%(15/240)。
- RS≥26组复发转移率23.4%(11/47),其中局部复发0.0%(0/47),远处转移23.4%(11/47)。
- RS<26组和RS≥26组5年无复发生存率分别为93.8%(95%CI:90.7%-96.9%)和87.2%(95%CI:78.2%-97.3%),P=0.007。
- RS<26组和RS≥26组5年无病生存率分别为92.1%(95%CI:88.7%-95.6%)和85.1%(95%CI:75.5%-95.9%),P=0.006。
关键数值与推荐
- 单因素分析显示年龄、肿瘤最大径、组织学分级、PR表达、Ki-67指数及RS与DFS有关(均P<0.05)。
- 多因素分析显示年龄和肿瘤最大径为DFS的独立影响因素(均P<0.05)。
临床怎么用
- 对于激素受体阳性T1-3N1M0期乳腺癌,21基因RS可辅助评估远处转移和DFS风险。
- RS≥26提示远处转移风险较高、DFS较短,需加强随访和个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the association of 21-gene recurrence score (RS) and clinicopathologic characteristics of hormone receptor (HR) positive T1-3N1M0 breast cancer and its value in prognosis evaluation. Methods: The clinicopathological data of 287 patients with T1-3N1M0 breast cancer were collected, the 21-gene assay was completed, and follow-up was conducted. According to the 21-gene RS, the patients were divided into the RS<26 and RS≥26 groups. The relationship between the 21-gene RS and clinicopathological characteristics, treatment, recurrence, and metastasis was analyzed. Univariate and multivariate statistical analyses were used to analyze the risk factors for disease free survival (DFS). Results: The median RS of the 287 patients was 16. There were 240 cases with RS <26 and 47 cases with RS≥26. Tumor size, grade, estrogen receptor (ER), progesterone receptor (PR), and Ki-67 index were significantly different between the two cohorts (P<0.05 for all). After a median follow-up of 74 months, the recurrence rate in the RS<26 group (8.3%) was significantly lower than that in the RS≥26 group (23.4%), the locoregional recurrence (LRR) rates in the RS<26 and RS≥26 groups were 2.1% and 0%,and the distant metastasis (DM) rates were 6.3% and 23.4%, respectively. The 5-year relapse free survival (RFS) rates of patients with RS<26 and RS≥26 were 93.8% (95% CI: 90.7%-96.9%) and 87.2% (95% CI: 78.2%-97.3%), and the 5-year DFS rates were 92.1% (95% CI: 88.7%-95.6%) and 85.1% (95% CI: 75.5%-95.9%), respectively, with significant differences between the two cohorts (P=0.007 and P=0.006, respectively). Univariate analysis showed age, tumor size, grade, PR status, Ki-67 index and RS were prognostic factors for DFS (P<0.05 for all). Multivariate analysis showed that age and tumor size were independent significant predictors for DFS (P<0.05). Conclusions: The 21-gene RS of T1-3N1M0 breast cancer is related to tumor size, grade, ER, PR, and Ki-67 index. RS is an important factor affecting DM and DFS. 目的: 探讨激素受体阳性T1~3N1M0期乳腺癌21基因复发风险评分(RS)与临床病理特征的关系及其在预后评估中的价值。 方法: 收集287例T1~3N1M0期乳腺癌患者的临床病理资料,完成其乳腺癌石蜡包埋组织的21基因检测,随访获取复发转移及生存资料。将患者分为RS<26分组和RS≥26分组,分析21基因RS与临床病理特征、治疗以及复发转移的关系,采用单因素和多因素Cox回归分析明确患者无病生存时间(DFS)的影响因素。 结果: 287例乳腺癌患者中位RS为16分。RS<26分组240例,RS≥26分组47例。RS<26分组与RS≥26分组肿瘤最大径、组织学分级、雌激素受体(ER)表达、孕激素受体(PR)表达、Ki-67指数差异均有统计学意义(均P<0.05),乳腺手术方式、腋窝手术方式、内分泌治疗、化疗和放疗差异均无统计学意义(均P>0.05)。中位随访74个月,RS<26分组的复发转移发生率为8.3%(20/240),其中局部复发率为2.1%(5/240),远处转移率为6.3%(15/240)。RS≥26分组的复发转移发生率为23.4%(11/47),其中局部复发率为0.0%(0/47),远处转移率为23.4%(11/47)。RS<26分组的乳腺癌特异性死亡率和总死亡率同样低于RS≥26分组(0.8%和10.6%,0.8%和14.9%)。RS<26分组和RS≥26分组患者的5年无复发生存率分别为93.8%(95% CI:90.7%~96.9%)和87.2%(95% CI:78.2%~97.3%),5年无病生存率分别为92.1%(95% CI:88.7%~95.6%)和85.1%(95% CI:75.5%~95.9%),差异均有统计学意义(P值分别为0.007和0.006)。单因素Cox回归分析显示,年龄、肿瘤最大径、组织学分级、PR表达、Ki-67指数及RS与DFS有关(均P<0.05)。多因素Cox回归分析显示,年龄和肿瘤最大径为DFS的独立影响因素(均P<0.05)。 结论: 激素受体阳性T1~3N1M0期乳腺癌21基因RS与肿瘤最大径、组织学分级、ER表达、PR表达及Ki-67指数有关,21基因RS是影响激素受体阳性T1~3N1M0期乳腺癌远处转移和DFS的重要因素。.
引用
- Zhang YN, Qu Y, Mao F, et al. [Prognosis analysis and 21-gene recurrence score assay applied in hormone receptor positive T1-3N1M0 breast cancer patients]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41287312. doi:10.3760/cma.j.cn112152-20250205-00039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。